Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03991936 · ClinicalTrials.gov registry record · Phase 4
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03991936: Completed Phase 4 study, sponsored by Weill Medical College of Cornell University.
NCT03991936 is a Phase 4 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03991936, a Phase 4 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
Primary Outcome
The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.
Interventions
- DRUG Placebos
- DRUG Triamcinolone Acetonide 2.5 mg/mL
- DRUG Triamcinolone Acetonide 5.0 mg/mL
- DRUG Triamcinolone Acetonide 7.5 mg/mL
- DRUG Triamcinolone Acetonide 10 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2023-03-29 |
| Phase | Phase 4 |
What the finished NCT03991936 record still lists
NCT03991936 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebos is the first listed.
NCT03991936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03991936 about?
NCT03991936 is a clinical study titled "Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis". This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
What is the current status of trial NCT03991936?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2020-03-11. Estimated completion is 2023-03-29.
What interventions are being tested in trial NCT03991936?
The interventions under investigation include: Placebos (DRUG), Triamcinolone Acetonide 2.5 mg/mL (DRUG), Triamcinolone Acetonide 5.0 mg/mL (DRUG), Triamcinolone Acetonide 7.5 mg/mL (DRUG), Triamcinolone Acetonide 10 mg/mL (DRUG).
Who is sponsoring clinical trial NCT03991936?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03991936's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI